ArticleJournal of nuclear medicine : official publication, Society of Nuclear Medicine2018
A Prospective Comparison of
Registry-linked trialOpen access · bronzeAbstract readClinical Trial, Phase I
In one paragraph
Article in Journal of nuclear medicine : official publication, Society of Nuclear Medicine, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02190279 (A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer), which is not on this map. Cited by 28 papers.
0numbers the graph read from it
0cells of the map it votes in
28citing papers in PubMed
5.9field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
A Pilot Study of 18F-DCFBC PET/CT in Prostate Cancer
Who cites it
28 citing papers in PubMed, 45 citations in OpenAlex.
- Prospective Comparison of PET Imaging with PSMA-TargetedJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2020Trial
- Bone metastases of prostate cancer: Molecular mechanisms, targeted diagnosis and targeted therapy (Review).Oncology reports · 2025Review
- Biological determinants of PSMA expression, regulation and heterogeneity in prostate cancer.Nature reviews. Urology · 2025Review
- Article
- Clinical advancement of precision theranostics in prostate cancer.Frontiers in oncology · 2023Review
- A Retrospective Comparative Study of Sodium Fluoride NaLife (Basel, Switzerland) · 2022Article
- The future of PSMA PET and WB MRI as next-generation imaging tools in prostate cancer.Nature reviews. Urology · 2022Review
- A Comparison ofJournal of nuclear medicine : official publication, Society of Nuclear Medicine · 2022Article
- Application of SPECT and PET / CT with computer-aided diagnosis in bone metastasis of prostate cancer: a review.Cancer imaging : the official publication of the International Cancer Imaging Society · 2022Review
- Comparison ofEuropean journal of hybrid imaging · 2022Article
- DOTA Conjugate of Bisphosphonate and PSMA-Inhibitor: A Promising Combination for Therapy of Prostate Cancer Related Bone Metastases.Frontiers in nuclear medicine · 2022Article
- Current and future targeted alpha particle therapies for osteosarcoma: Radium-223, actinium-225, and thorium-227.Frontiers in medicine · 2022Review
- Tumor Response to Radiopharmaceutical Therapies: The Knowns and the Unknowns.Journal of nuclear medicine : official publication, Society of Nuclear Medicine · 2021Review
- Monitoring PSMA Responses to ADT in Prostate Cancer Patient-Derived Xenograft Mouse Models Using [Molecular imaging and biology · 2021Article
- Review
- 68Ga-PSMA-11 PET/CT Follow-Up of Patients with Prostate Cancer with Bone Metastases Who Had Reduced Bone Density after Androgen Deprivation Therapy.Diagnostics (Basel, Switzerland) · 2021Article
- Meeting report from the Prostate Cancer Foundation PSMA theranostics state of the science meeting.The Prostate · 2020Review
- The Potential Role for Immunotherapy in Biochemically Recurrent Prostate Cancer.The Urologic clinics of North America · 2020Review
- Imaging diagnosis of metastatic breast cancer.Insights into imaging · 2020Review
- [Recent progress of positron radionuclide labeled small molecule inhibitors of prostate specific membrane antigen for PET/CT imaging of prostate cancer].Sheng wu yi xue gong cheng xue za zhi = Journal of biomedical engineering = Shengwu yixue gongchengxue zazhi · 2020Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
17 authors at 5 institutions in 1 country.
Stephanie A HarmonClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., National Cancer Institute, Campus at Frederick, Frederick, Maryland stephanie.harmon@nih.gov.
Ethan BergvallMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Esther MenaMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Joanna H ShihDivision of Cancer Treatment and Diagnosis: Biometric Research Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Stephen AdlerClinical Research Directorate/Clinical Monitoring Research Program, Leidos Biomedical Research, Inc., National Cancer Institute, Campus at Frederick, Frederick, Maryland.
Yolanda McKinneyMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Sherif MehralivandMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Deborah E CitrinRadiation Oncology Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Anna CouvillonGenitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Ravi A MadanGenitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
James L GulleyGenitourinary Malignancies Branch, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Ronnie C MeaseRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
Paula M JacobsCancer Imaging Program, National Cancer Institute, National Institutes of Health, Rockville, Maryland.
Martin G PomperRussell H. Morgan Department of Radiology and Radiological Science, Johns Hopkins University School of Medicine, Baltimore, Maryland; and.
Baris TurkbeyMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
Peter L ChoykeMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
M Liza LindenbergMolecular Imaging Program, National Cancer Institute, National Institutes of Health, Bethesda, Maryland.
National Cancer Institute · USNational Institutes of Health · USJohns Hopkins Medicine · USJohns Hopkins University · USLeidos Biomedical Research Inc. (United States)
Funding
CCR NIH HHS HHSN261200800001CNCI NIH HHS HHSN261200800001E
Abstract
The purpose of this study was to compare the diagnostic performance of
Indexed as
Fluorine RadioisotopesRadiopharmaceuticalsAdultAgedAged, 80 and overAntigens, SurfaceBone NeoplasmsCysteineGlutamate Carboxypeptidase IIHumansMaleMiddle AgedPositron Emission Tomography Computed TomographyProspective StudiesProstatic NeoplasmsSoft Tissue NeoplasmsAntigens, SurfaceCysteineFluorine-18Fluorine RadioisotopesFOLH1 protein, humanGlutamate Carboxypeptidase IIN-(N-((S)-1,3-Dicarboxypropyl)carbamoyl)-4-(18F)fluorobenzyl-L-cysteineRadiopharmaceuticalsmetastatic prostate cancerNaFPET/CT imagingPSMA
Identifiers
What OpenQuestion holds
Textmetadata
Read underepoch 390
Registered trials
NCT02190279ClinicalTrials.gov
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.